Table 1.
Baseline characteristics.
| Placebo | Naftopidil 75 mg | p-value | |
|---|---|---|---|
| Number of patients | 49 | 43 | |
| Age, mean (SD) (years) | 52.35 ± 13.43 | 50.88 ± 13.78 | 0.608 |
| Sex, no (%) | 0.048 | ||
| Male | 23 (46.9) | 29 (67.4) | |
| Female | 26 (53.1) | 14 (32.6) | |
| Body mass index, mean (SD) (kg/m2) | 24.07 ± 3.56 | 24.61 ± 4.98 | 0.550 |
| Stone size, mean (SD) (mm) | 9.33 ± 6.27 | 11.25 ± 6.09 | 0.142 |
| Stone location (%) | 0.784 | ||
| Right | 21 (42.9) | 16 (37.2) | |
| Left | 25 (51.0) | 25 (58.1) | |
| Bilateral | 3 (6.1) | 2 (4.7) | |
| Stone position (%) | 0.766 | ||
| Kidney | 14 | 18 | |
| Upper ureter | 8 | 7 | |
| Mid ureter | 6 | 6 | |
| Low ureter | 12 | 6 | |
| Multiple site | 9 | 6 | |
| Preoperative IPSS | 9.33 ± 6.84 | 9.35 ± 6.83 | 0.988 |
| Preoperative IPSSstorage | 4.27 ± 3.13 | 4.09 ± 3.11 | 0.792 |
| Preoperative IPSSvoiding | 5.06 ± 4.67 | 5.26 ± 4.71 | 0.843 |
| Preoperative QoL | 2.82 ± 1.70 | 2.35 ± 1.51 | 0.173 |
| Surgery type (%) | 0.476 | ||
| URS with rigid ureteroscope | 22 (44.9) | 16 (37.2) | |
| URS with flexbile ureteroscope | 4 (8.2) | 2 (4.7) | |
| RIRS without UAS | 1 (2.0) | 0 (0.0) | |
| RIRS with UAS | 22 (44.9) | 25 (58.1) | |
| Presence of preoperative Double-J stenting | 13 (26.5) | 13 (30.2) | 0.694 |
| Duration of double-J ureteral stent | 12.09 ± 5.59 | 10.81 ± 3.90 | 0.220 |
SD, standard deviation; IPSS, international prostate symptom score; URS, ureteroscopy; RIRS, retrograde intrarenal surgery; UAS, ureteral access sheath.